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 1	
Summary 2	
Background: Microalbuminuria is an early sign of kidney disease in diabetes and indicates 3	
cardiovascular risk. We tested if a prespecified urinary proteomic risk classifier (CKD273) was 4	
associated with development of microalbuminuria and if progression to microalbuminuria could be 5	
prevented with the mineralocorticoid receptor antagonist spironolactone.  6	
Methods: Prospective multicentre study in people with type 2 diabetes, normal urinary albumin 7	
excretion and preserved renal function in 15 European specialist centres. High-risk individuals 8	
determined by CKD273 were randomised 1:1 (interactive web response system) in a double-blind 9	
randomised controlled trial comparing spironolactone 25 mg o.d. to placebo. Primary endpoint was 10	
development of confirmed microalbuminuria in all individuals with available data. Secondary 11	
endpoints included reduction in incidence of microalbuminuria with spironolactone and association 12	
between CKD273 and impaired renal function defined as a glomerular filtration rate < 60 ml/min 13	
per 1·73 m2. This study is registered with ClinicalTrials.gov: NCT02040441 and is completed. 14	
Findings: From March 25, 2014 to September 30, 2018 we followed 1775 participants, 12% 15	
(n=216) had high-risk urinary proteomic pattern of which 209 were included in the trial and 16	
assigned spironolactone (n=102) or placebo (n=107). Median follow-up time was 2·51 years (IQR 17	
2·0-3·0). Progression to microalbuminuria was seen in 28·2% of high-risk and 8·9% of low-risk 18	
people (P< 0·001) (hazard ratio (HR), 2·48; 95% confidence interval [CI], 1·80 to 3·42 P<0·001, 19	
independent of baseline clinical characteristics). A 30% decline in eGFR from baseline was seen in 20	
42 (19·4 %) high-risk participants compared to 62 (3·9 %) low-risk participants, HR 5·15; 95 % CI 21	
(3·41 to 7·76; p<0.0001). Development of microalbuminuria was seen in 35 (33%) randomised to 22	
placebo and 26 (25%) randomised to spironolactone treatment (HR 0·81, 95% CI, 0·49 to 1·34, 23	
P=0·41). Harms: hyperkalaemia was seen in 13 versus 4, and gynaecomastia in 3 versus 0 subjects 24	
on spironolactone and placebo, respectively. 25	
Interpretation: In people with type 2 diabetes and normoalbuminuria, the urinary proteomic 26	
classifier CKD273 was associated with a 2·5 times increased risk for progression to 27	
microalbuminuria over a median of 2·5 years, independent of clinical characteristics. 28	
Spironolactone did not prevent progression to microalbuminuria in high-risk subjects.  29	
Funding: The European Union Seventh Framework Programme (FP7/2007-2013) under grant 30	
agreement no. 279277. 31	
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Research in context 4	
Evidence before this study 5	
We searched PubMed from Jan 1, 1990 to Jun 30, 2019, for all English-language publications, 6	
using the search terms “type 2 diabetes”, “normoalbuminuria”, “urinary proteomics”, “urinary 7	
peptidomics”, “spironolactone”, “mineralocorticoid receptor antagonist”, “aldosterone antagonist”, 8	
“albuminuria”, “kidney disease”, “nephropathy”. Posthoc studies of cross sectional and longitudinal 9	
cohorts of persons with type 2 diabetes and non-diabetic kidney disease have been investigated with 10	
urinary proteomics as a marker of presence of kidney disease or a marker of development of kidney 11	
disease. The urinary peptide pattern for chronic kidney disease consisting of 273 peptides 12	
(CKD273) was demonstrated to be associated with progression of albuminuria or loss of renal 13	
function in such retrospective cohorts, but no studies were prospective or had the risk marker linked 14	
to a potential intervention. Mineralocorticoid receptor antagonists (MRA) have been demonstrated 15	
to lower urinary albumin excretion in short term studies of patients with moderate to severely 16	
elevated albuminuria, but long-term data are lacking, and studies aiming to prevent progression of 17	
normo- to microalbuminuria have not been done.  18	
Added value of this study 19	
To our knowledge, this paper describes the first prospective multicentre study evaluating the multi-20	
dimensional CKD273 urinary proteomic classifier for risk stratification in individuals with 21	
normoalbuminuria and type 2 diabetes. This study demonstrates that CKD273 is effective as an 22	
early marker of risk for progression to persistent microalbuminuria in a prospective trial setting, and 23	
in addition is associated with development of impaired renal function. 24	
This study tested whether the mineralocorticoid receptor antagonist spironolactone could delay or 25	
prevent development of confirmed microalbuminuria in subjects identified to be at high risk of 26	
progression based on the CKD273 proteomic biomarker. This was not demonstrated. 27	
Implications of all the available evidence 28	
6	
	
Collectively, all the evidence suggests that the urinary proteomic based risk marker CKD273 is 1	
associated with early progression of diabetic kidney disease, with added value to the clinical 2	
characteristics being used today in the clinic including urinary albumin excretion and glomerular 3	
filtration rate. The early progression cannot be mitigated by treatment with the MRA 4	
spironolactone.5	
7	
	
 1	
Introduction 2	
Diabetic kidney disease (DKD) is a frequent and costly complication of diabetes as well as a 3	
leading cause of renal failure. In addition, DKD is associated with a significantly increased burden 4	
of cardiovascular disease (CVD). Globally 1 in 11 adults has diabetes, and numbers are increasing 5	
according to the International Diabetes Federation Atlas from 2019. Despite an observed reduction 6	
in relative risk for end stage kidney disease (ESKD) in diabetes during the last decades the absolute 7	
number of people referred for ESKD treatment has more than doubled 1. This likely results from the 8	
increasing prevalence of diabetes, combined with reduction in competing CVD mortality and 9	
increased eligibility for treatment of ESKD. The current situation mandates better prediction, 10	
prevention and treatment of DKD.  11	
In clinical practice, DKD is diagnosed by albuminuria and/or decrease in estimated glomerular 12	
filtration rate (eGFR). Microalbuminuria is a marker of increased risk for CVD and ESKD.2 13	
Treatment of micro- and macroalbuminuria with renin-angiotensin aldosterone system (RAAS) 14	
blocking agents and control of cardiovascular risk factors has improved outcomes,3 but the 15	
prognosis remains poor and many still progresses despite widespread prescribing of these agents as 16	
advocated by clinical guidelines. Recently studies have suggested pleiotropic and kidney protective 17	
effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors and potentially glucagon-like 18	
peptiode-1 (GLP1) receptor agonists and they are now recommended by guidelines in type 2 19	
diabetes (T2D) with established DKD4.  20	
Studies into prevention of microalbuminuria with angiotensin converting enzyme inhibitors (ACEi) 21	
or angiotensin II receptor blockers (ARBs) have shown conflicting results.5,6 Biomarkers to identify 22	
people who stand to benefit most from preventative therapy would therefore be helpful. Depending 23	
on the pathophysiology underlying the biomarker this could also help guide intervention and 24	
precision medicine in DKD. Good et al. previously described a high dimensional urinary biomarker 25	
pattern composed of 273 peptides associated with overt kidney disease: CKD273.7 The original 26	
studies included people with chronic kidney disease (CKD) on a mixed background. It has been 27	
possible to develop risk scores with the same methodology that are optimised for diagnosis of 28	
different kidney diseases, but the CKD273 has been robust across multiple causes of CKD 29	
including DKD. In retrospective studies this proteomic classifier identified subjects at risk for DKD 30	
8	
	
and progression in albuminuria class earlier than the indices currently used in clinical practice8-10. 1	
However, all data on CKD273 to date derive from post hoc analyses of previously conducted 2	
studies and analyses of stored samples. 3	
Blocking the RAAS has been recommended in DKD, and it was suggested that more complete 4	
inhibition of the RAAS with mineralocorticoid receptor antagonists (MRA) like spironolactone 5	
added to RAAS inhibition could further improve renal protection 11,12. A further reduction in 6	
albuminuria of approximately 20-30% was seen in short-term studies and anticipated to predict 7	
beneficial renal effects. Long-term data from phase 3 trials focused on endpoints such as ESKD are 8	
missing, as are studies using spironolactone to prevent the earlier stages of DKD. The components 9	
of CKD273 include collagen fragments and are assumed to relate to early fibrosis in the kidney. 10	
Therefore, spironolactone considered antifibrotic via blockade of aldosterone seemed a relevant 11	
intervention. 12	
The “Proteomic prediction and renin angiotensin aldosterone system inhibition prevention of early 13	
diabetic nephropathy in type 2 diabetic participants with normoalbuminuria” (PRIORITY) study 14	
aimed to test the following: 1) to demonstrate that CKD273 is associated with development of 15	
persistent microalbuminuria in people with T2D and normoalbuminuria in a prospective study; 2) to 16	
determine whether intervention with a mineralocorticoid receptor antagonist (spironolactone) 17	
compared to placebo reduces the increased risk of developing microalbuminuria in people with a 18	
high-risk CKD273 pattern. Albuminuria is used as a biomarker in the clinic, in trials and also here 19	
as the endpoint for early progression of DKD, making it inheritably difficult for a new marker such 20	
as CKD273 to perform better than albuminuria. Thus, we also looked at changes in eGFR as 21	
secondary outcomes as well as potential harms. 22	
 23	
Methods 24	
Study design and participants 25	
PRIORITY is an investigator-initiated, prospective, double-blind, randomised, placebo-controlled 26	
international multicentre clinical and observational study in people with T2D and 27	
normoalbuminuria funded by the European Commission’s Seventh Framework programme. The 28	
detailed rationale, study design and methods for PRIORITY have been published elsewhere.13 Each 29	
9	
	
partner was represented in the steering group, and the partner Hannover Clinical Trial Centre was 1	
responsible for data management and study monitoring. 2	
The protocol and amendments were approved by the respective national competent authorities using 3	
in part the Voluntary Harmonisation Procedure and by the institutional local ethics committees (see 4	
supplementary material).  The study was conducted in accordance with the International Conference 5	
on Harmonisation – Good clinical practice (ICH-GCP) and Declaration of Helsinki. Participants 6	
provided written informed consent. Pharmacovigilance was performed at Medizinsche Hochschule 7	
Hannover Germany and an external independent data monitoring committee (DMC) monitored 8	
safety (not efficacy) throughout the study based on data from HCTC analysed by the DMC 9	
statistician. Safety focus was on serious adverse events, decline in eGFR >30 and 40% from 10	
baseline, hyperkalaemia and gynecomastia. EU Clinical Trials Register (EudraCT: 2012-000452-11	
34) and http://www.clinicaltrial.gov (NCT02040441) accessed Jan 5th 2020. 12	
From March 25, 2014 to the end of inclusion on August 31, 2016, people aged 18-75 years with 13	
T2D, preserved kidney function and normoalbuminuria were included and followed till September 14	
30, 2018. Main inclusion criteria were: normoalbuminuria (ratio of urine albumin [mg] to creatinine 15	
[g] (UACR) <30) in at least two out of three consecutive morning void urine samples and eGFR) 16	
>45 ml per minute per 1·73 m2 of body-surface area at screening. Information on pre-study 17	
albuminuria was not collected. Main exclusion criteria were use of dual RAAS blockade or MRA, 18	
or heart failure requiring MRA. Participants were stratified into high- or low-risk groups based on 19	
their CKD273 score, of a single random spot urine sample collected at screening (for details see 20	
supplementary material). High-risk was defined as CKD273classifier score >0·154, low-risk as ≤ 21	
0·154 as previously described.9,13All data are normalised to 28 collagen fragments in urine not 22	
affected by disease and variability is low 14. 23	
Randomisation and masking 24	
Participants in the high-risk group were randomly assigned in a double-blind fashion to either oral 25	
spironolactone 25 mg o.d. or matching placebo. Participants in the high-risk group were randomly 26	
assigned in a double-blind fashion stratified by centre and RAAS treatment (yes/no) (1:1 using an 27	
interactive web response system (see supplementary document for further details) to either 28	
spironolactone 25 mg o.d. or matching placebo using a computer generated randomisation scheme 29	
stratified based on use of RAAS blocking agents. There was no difference in appearance between 30	
10	
	
the medications for each treatment group. Medications for each treatment group were supplied in 1	
identical bottles labelled appropriately to maintain masking within the study. Participants and 2	
investigators were masked to group assignment. Subjects continued ongoing medication including 3	
RAAS inhibitors according to local standards of care. All participants in the low-risk group were 4	
followed without study intervention and continued treatment according to local guidelines.  5	
Procedures 6	
Participants with a high-risk proteomics pattern were provided with study medication after 7	
randomisation and seen for a safety visit at the study centre after 2 weeks, with local measurement 8	
of creatinine and potassium. Every 13th week, participants were seen in the clinic and provided 9	
with the study drug. At each visit, UACR was tested in three consecutive urine samples, and locally 10	
measured biochemistry was analysed. Standard of care treatment was encouraged for all. 11	
Participants with a low-risk CKD273 pattern were seen once yearly after the baseline visit and 12	
tested for UACR in three consecutive urine samples as well as locally measured biochemistry. 13	
Samples were analysed locally with standardised methods, as described previously.15eGFR was 14	
calculated centrally using CKD-EPI equation. UACR was measured at the central laboratory: Steno 15	
Diabetes Center Copenhagen, Denmark (SDCC) using Vitros® 5600 MicroSlide (Orto Clinical 16	
Diagnostics, New Jersey, USA).  17	
Urine proteomics was performed by applying capillary electrophoresis mass spectrometry (CE-MS) 18	
analysis at the central laboratory at Mosaiques Diagnostics in Hannover, Germany. This provides 19	
data on >1000 identified proteins or peptides and a predefined renal risk profile based on 273 20	
peptides (CKD273). 13,16 Originally a threshold was identified to separate subjects with CKD from 21	
healthy controls. Based on a post hoc analysis of CKD273 as a marker of progression from 22	
normoalbuminuria to microalbuminuria, we had a priori defined a threshold for CKD273 of >0·154 23	
corresponding to the 20% percentile indicating high risk for progression from normo- to 24	
microalbuminuria . 25	
Outcomes 26	
The primary objective was to confirm that urinary proteomics is associated with development of 27	
confirmed microalbuminuria in people with T2D and normoalbuminuria. The primary endpoint was 28	
development of confirmed microalbuminuria in people with T2D and normoalbuminuria. 29	
11	
	
Confirmed microalbuminuria was defined as UACR>30 mg/g in at least two out of three first 1	
morning voids with 30% increase (geometric mean) in UACR from “run-in-phase” samples or >40 2	
mg/g (geometric mean). 3	
The secondary objective was to investigate if therapy with spironolactone 25 mg o.d. reduces risk 4	
of transition to microalbuminuria in those patients identified to be at high risk. Additional 5	
objectives were to compare the rates of change in UACR and eGFR in the high vs. low-risk groups, 6	
to compare the effect of spironolactone on rate of change in UACR in the intervention group and to 7	
study the association between the urinary proteomic patterns and renal events during the study 8	
including development of CKD 3 (for patients with eGFR>60 at baseline), slope of eGFR, and as a 9	
sensitivity measure >30 and 40% decline in eGFR from baseline or doubling of serum creatinine, 10	
based on one-time measurements of eGFR without requirement of confirmation by repeat testing. 11	
Safety outcome of special interest in the randomised high-risk population randomised in the 12	
intervention study included hyperkalaemia (plasma or serum level of potassium >0.4 mmol/L above 13	
local upper reference) and gynaecomastia. During hyperkalaemia the study medication was paused 14	
and could be restarted when potassium was normal. Adverse events and serious adverse events were 15	
recorded for the intention to treat study population and was not collected in the observational cohort 16	
(low risk patients).  17	
Statistical analysis  18	
Sample size for the primary objective of association between CKD273 status (high/low risk) and 19	
development of persistent microalbuminuria was smaller (n=333, see expanded statistical section in 20	
supplement) than for the secondary objective the effect of spironolactone vs. placebo in CKD273 21	
high risk participants. So, in order to address the second objective more patients than needed for 22	
objective one was included. High-risk subjects were expected to comprise 15 % of the screened and 23	
included participants. Using the samples size formula for two proportions test (α = 0·05, β = 0·80), 24	
randomised (1:1), 129 subjects in each arm of the intervention group would provide sufficient 25	
power to find 40% effect. We estimated that the study required 2000 subjects to be included in the 26	
observation cohort to accomplish this.  The sample size was reduced by an amendment after a 27	
revised sample size calculation based on a review of the treatment effect of mineralocorticoid 28	
receptor antagonists12. Follow up time was also modified with the amendment (see details of 29	
amendments in supplementary material including the study protocol). Continuous variables are 30	
12	
	
reported as means with standard deviation (SD) for normally distributed data or median with 1	
interquartile range (IQR) for skewed data and are compared between groups using an unpaired t-test 2	
where skewed data are log transformed before comparison between groups. A chi-square test is 3	
used for comparison of categorical data. In the observation cohort for the primary objective, 4	
including all participants with valid proteomic score and data at baseline visit, a comparison 5	
between progression to persistent microalbuminuria in the high- and low-risk stratum was 6	
conducted using an unadjusted Cox-regression model with chi-square  test. In addition, adjustment 7	
for age, sex, Hba1c, systolic blood pressure, retinopathy, eGFR and UACR at baseline was 8	
performed. For the secondary objective (effect of spironolactone in high-risk subjects), a 9	
comparison between spironolactone and placebo treatment was performed in the intention to treat 10	
cohort with a Cox-regression model including data on the primary outcome. The intention to treat 11	
cohort comprised all participants with a valid proteomic score with a high-risk pattern who were 12	
provided with study medication. To evaluate changes in UACR and eGFR over time a linear mixed 13	
model was applied and for UACR with adjustment for UACR at baseline followed by truncation to 14	
weeks in the study period. A two-tailed p value of <0·05 was considered significant. SAS 15	
Enterprise Guide version 7·1 (7.100.1.2711) (64-bit) by SAS Institute, Inc., Cary, NC, USA was 16	
used for statistical analysis.  17	
Role of the funding source 18	
The study was overseen by an steering committee, not including members from the study funder. 19	
The funder had no role in the design of the study, the collection and analysis of the data, or writing 20	
of the report. All authors had access to the study results, and the first authors and corresponding 21	
author vouch for the accuracy and completeness of the data reported and had access to all data. The 22	
first authors and the steering committee had the final decision to submit for publication. 23	
Results 24	
From March 25, 2014 through August 31, 2016, a total of 2277 persons from 15 study centres in 10 25	
countries were screened and 1775 participants included. Of those, 216 participants were in the high-26	
risk group and 1559 participants were in the low-risk group corresponding to a proportion of 12·3% 27	
high-risk participants. The main reason for screen failure was presence of microalbuminuria 28	
(n=133) (Figure 1). Baseline characteristics are presented in Table 1. In comparison to low-risk 29	
13	
	
individuals, the high-risk group were more likely to be male, and were older with longer diabetes 1	
duration, a lower eGFR and a higher UACR (P<0·02; Supplementary Table S1 and S2). 2	
The trial ended with last study visit on September 30, 2018. The median follow-up time was 2·51 3	
years (IQR 2·0-3·0). In the low risk group 150 subjects (9·6%) did not complete the follow-up 4	
period (Figure 1). Of the 216 high-risk participants 209 were randomised to either placebo or 5	
spironolactone. Median follow-up time in the intervention study was 2·5 years (IQR 2·0-3·1) and 6	
36 participants (17 %) dropped out (Figure 1). During follow up there was more subjects in the 7	
high-risk group compared to low risk, who initiated treatment with glucose and blood pressure 8	
lowering medication, but no difference between the intention to treat groups (see table S6). 9	
The primary endpoint of confirmed microalbuminuria was more frequent in high-risk individuals 10	
based on CKD273 where 61 of 216 (28·2%) developed the endpoint compared to 139 of 1559 11	
(8·9%) low-risk individuals (p<0·0001) (Figure 2A).  In a Cox-model the HR (high vs. low-risk) 12	
was 3·92; 95% confidence interval (CI), 2·90 to 5·30; p<0·0001. After adjustment for baseline age, 13	
sex, HbA1c, systolic blood pressure, retinopathy, UACR and eGFR the HR was 2·48; 95% CI, 1·80 14	
to 3·42; p<0·0001. Additional adjustment for glucose lowering or antihypertensive and diuretic 15	
medication at baseline or started during follow up, or for HbA1c during follow up, did not change 16	
the HR for CKD273 (Table S5+6). Endpoints given in Table 2. 17	
In participants with eGFR>60 ml per minute per 1·73m2 at baseline (n=1666), development of CKD 18	
stage 3 (eGFR<60 ml per minute per 1·73 m2) was more frequent in high-risk individuals (n=48; 19	
25·5%) compared to 119 (8·1%) low-risk individuals, (HR 3·93; 95% CI, 2·81 to 5·50) (Figure 20	
2B). Few participants developed CKD stage 4 (eGFR<30 ml per minute per 1·73 m2) during the 21	
trial period (7 (3·2%) in high-risk vs 3 (0·19%) in low-risk individuals (HR 16·70; 95% CI, 4·31 to 22	
64·67). A decline in eGFR of 30% from baseline was seen in 42 (19·4 %) high-risk participants 23	
compared to 62 (3·9 %) low-risk participants, HR for CKD273 high-risk participants was 5·15; 95 24	
% CI (3·41 to 7·76; p<0.0001) after adjustment for eGFR and UACR. A 40 % decline in eGFR 25	
from baseline was seen in 15 (6.9 %) high-risk participants compared to 22 (1.4 %) low-risk 26	
participants, HR 4·84; 95 % CI (2·43 to 9·68; p<0.0001) adjusted for eGFR and UACR. A doubling 27	
in serum creatinine from baseline was seen in 9 (4.17 %) high-risk vs. 9 (0.58 %) low-risk 28	
participants, HR 7·49, 95 % CI 2·97 to 18·90, p < 0·0001. No participants developed ESKD. 29	
14	
	
In agreement with this, we found a faster progression of albuminuria in high-risk participants, after 1	
adjustment for baseline UACR: 7·1 (SE 1·14) %/year, compared with low risk 2·6 (0·85) %/ year. 2	
Similarly, eGFR decline was faster in high-risk participants (Figure S3A). There was no difference 3	
in HbA1c or blood pressure during the study in high-risk vs. low-risk people (Figure S2). Adjusting 4	
for mean HbA1c during follow up or new antihypertensive or glucose lowering medication did not 5	
change the results. 6	
For the secondary objective: effect of spironolactone in high-risk individuals according to CKD273 7	
we found in the randomised study of spironolactone compared to placebo, that there was no 8	
significant difference in the development of the primary endpoint “confirmed microalbuminuria” 9	
between groups, as 35 of 107 (32·7%) placebo-treated individuals developed the endpoint 10	
compared to 26 (25·5%) of 102 individuals in the spironolactone group (HR 0·81; 95% CI, 0·49 to 11	
1·34; p=0·41) (Figure 3 and S6). We had anticipated a 40% reduction in albuminuria progression, 12	
which cannot be excluded as it is within the 95% CI. Additional adjustment for glucose lowering or 13	
antihypertensive and diuretic medication started during follow up, or for HbA1c during follow up, 14	
did not change the HR for the intervention.  15	
Development of CKD stage 3 (in subjects with baseline eGFR>60 ml per min per 1·73 m2) was 16	
seen in 15 (16·7%) placebo-treated subjects and 33 (35·9%) spironolactone-treated subjects (hazard 17	
ratio 2·617; 95% CI, 1·42 to 4·82; Figure S5). There was no difference in change in eGFR over 18	
time in the two groups (Supplementary Figure S3B). A decline in eGFR of 30% occurred in 24 19	
(23·5 %) participants allocated to spironolactone compared to 18 (16·8 %) in the placebo group, 20	
(HR for the spironolactone treated group was 1·61; 95 % CI (0·87 to 2·96; p=0·13).  Few reached 21	
40% decline. 22	
Spironolactone-treated participants had similar HbA1c and blood pressure compared to placebo-23	
treated participants (Supplementary Figure S4). 24	
Adverse events are given for the intention to treat groups in tables 3, S4 and S5. Safety events of 25	
special interest, development of gynaecomastia resulted in discontinuation of study medication in 3 26	
(3%) spironolactone-treated participants; and none in the placebo group.  Hypotension led to 27	
discontinuation of study medication in a further 3 (3%) spironolactone-treated participants 28	
compared to 1 placebo-treated individual.  Elevated serum potassium >5·5 mmol/L) occurred in 13 29	
(13%) spironolactone-treated and 4 (4%) placebo-treated individuals.  30	
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Discussion 1	
To our knowledge, this is the first prospective trial using a proteomics-based signature for risk 2	
stratification followed by risk-based intervention. We found that in normoalbuminuric T2D 3	
individuals with preserved renal function higher CKD273 classifier scores were associated with 4	
increased risk for progression to confirmed microalbuminuria independent of clinical markers. The 5	
high-risk CKD273 pattern was also associated with decline in renal function evaluated as 6	
progression to CKD stage 3 and 4 or as decline in eGFR. This confirms our primary hypothesis that 7	
individual risk can be assessed early in the course of T2D based on urinary proteomics. Compared 8	
to placebo, treatment with the mineralocorticoid receptor antagonist spironolactone was not able to 9	
delay development of microalbuminuria or impaired renal function. 10	
In current practice, confirmed microalbuminuria is used as a marker of onset of DKD and increased 11	
CVD risk although the underlying pathology may vary. In the presence of established 12	
microalbuminuria, RAAS blockade reduces progression to macroalbuminuria,17 and multifactorial 13	
intervention targeting cardiovascular risk factors reduces renal and cardiovascular morbidity and 14	
mortality.18 Although microalbuminuria is the earliest clinical index of renal damage, histological 15	
changes may already be advanced by the time it is detectable,19thus earlier identification of at-risk 16	
individuals is imperative in order to guide targeted preventive therapy.20 Increases in urinary 17	
albumin to microalbuminuria or higher levels are strongly associated with progression to more 18	
serious clinical endpoints such as significant loss of renal function and eventually end stage kidney 19	
disease, but also to an increased risk for cardiovascular complications21. Furthermore, using 20	
progression to microalbuminuria as the endpoint is the only current option for a study of early 21	
intervention aiming to prevent or delay onset of DKD. In addition to the clinical utility, the 22	
CKD273 pattern could also be used for enrichment of future clinical studies, with a high-risk 23	
population for progression of albuminuria. 24	
Previous post hoc analyses of cross sectional or longitudinal studies, collected without applying 25	
standardised protocols for collection, storage, transportation or analysis of samples, demonstrated 26	
that a high CKD273 score was associated with progression of renal disease in persons with and 27	
without diabetes.10,22-24 Not all participants with elevated CKD273 risk score progressed to 28	
microalbuminuria within the trial with a median follow-up of 2·5 years. With longer follow-up 29	
more participants could potentially progress to microalbuminuria and the higher rate of drop out (17 30	
vs. 10%) in the high-risk group could have led to a small underestimation of progression. Previous 31	
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studies have suggested that an elevation of the risk score precedes development of increased 1	
albuminuria with 3-5 years.10 The increase in AUC of the ROC curve was statistically significant 2	
when adding CKD273 to the clinical variables. The clinical significance can be discussed, as the 3	
change in AUC was small (Fig S1). This may reflect that the AUC was already high (0·76) with the 4	
clinical variables alone and that AUC is a conservative measure of added value, which was 5	
supported by the statistically significant improvement in the discrimination index. It may also 6	
reflect that the CKD273 was not perfect with the current study design and duration. In 2672 7	
subjects primarily diagnosed with diabetes (type 1 and 2) in which study rapid eGFR decline was 8	
the primary endpoint,8 CKD273 had a stronger association with UACR in those with baseline 9	
eGFR>70 ml per min per 1·73 m2, supporting the use of CKD273 in the present study population 10	
with preserved renal function. In the current trial only 12·3% of participants were classified as high-11	
risk according to CKD273 score, which is less than the expected 15% based on a previous study 12	
cohort study of 700 individuals with T2D and normoalbuminuria.9 13	
The results of the proteomic analyses were available within three days. This demonstrates feasibility 14	
of the test in a clinical setting. At present, urinary proteomic analysis is a high-end technology with 15	
costs significantly higher than urine albumin testing. The analysis currently costs 850 Euro/sample 16	
and the laboratory can do the analysis on shipped samples as in the trial and has a scalable platform, 17	
but currently the method cannot be set up in local laboratories. Health economic analyses 18	
previously indicated that use of CKD273 could be cost effective in T2D at this price. It requires that 19	
the CKD273 score is associated with development of microalbuminuria, and that progression can be 20	
prevented or delayed with preventive treatment.25The current study confirms the first of these 21	
criteria. In particular, it could be cost saving in people at high risk of CVD related complications. If 22	
CVD risk is low it is not cost effective, but most people with T2D are at elevated CVD risk. 23	
Regardless of the potential cost-effectiveness, restrictions on reimbursement in health systems may 24	
still be a limitation. Particularly in settings where screening with low cost methods including 25	
albuminuria and eGFR has not been implemented. Alternative use could be in clinical trials for 26	
selection of high-risk individuals or for evaluation of response to interventions. 27	
Mineralocorticoid receptor antagonists have been shown to reduce albuminuria when added to 28	
ongoing RAAS blockade in subjects with diabetes and micro- or macroalbuminuria in short term 29	
trials of up to 1 year.26,27 The compounds are expected to reduce fibrosis, and as CKD273 to a large 30	
extent is composed of peptides related to changes in extracellular matrix,28 we expected 31	
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spironolactone to be effective in high-risk individuals. We did not demonstrate this, which could 1	
relate to study power, study duration or lack of effect in this population. It is a limitation that the 2	
number of high-risk participants randomised to intervention were lower than anticipated in the 3	
sample size calculation. The event rate in the placebo group was also lower than expected and thus 4	
power was reduced. Decline in eGFR over time was an additional secondary endpoint, which was 5	
similar in the two groups particularly if calculated from week 13 after the initial decline in eGFR 6	
(Table 2). In contrast more participants developed CKD stage 3 in the spironolactone groups 7	
compared to placebo, potentially due to acute hemodynamic effects (Figure S3B), and there was no 8	
significant increase in a 30% decline in eGFR from baseline. Treatment was well-tolerated. 9	
Alternative interventions which have recently demonstrated potential renal benefits in diabetes 10	
should be tested in high-risk individuals, such as non-steroidal mineralocorticoid receptor 11	
antagonists,29GLP1 receptor agonists or SGLT2 inhibitors4. 12	
Our trial has some limitations. The risk stratification to high- and low-risk was based on proteomic 13	
analysis of a single urine sample. We expect that the variation is limited due to the large number of 14	
peptides included in the pattern7.This issue has not been extensively studied, but repeatability has 15	
been tested with 100% correct classification of CKD cases and controls on multiple occasions. In 16	
addition, the relative intraassay coefficient was 7%.16 Microalbuminuria is an accepted clinically 17	
relevant surrogate for DKD, but not approved by regulatory agencies, although a recent conference 18	
with EMA and FDA discussed observational and clinical trial data showing a strong association 19	
between changes in albuminuria and long-term renal outcomes including ESKD.30Since the study 20	
was designed, relative changes in eGFR of 30 or 40% were suggested as outcome and high-risk 21	
based on CKD273 was strongly associated with these outcomes as well, although one-time 22	
measurements without repeated test for confirmation was used. The estimated hazard ratio for 23	
progression may be falsely low, as the high-risk group were treated with spironolactone or placebo, 24	
although this had no effect on albuminuria, but exclusion of subjects with high risk on active 25	
treatment did not change the hazard ratio (Supplementary Figure S6). Had spironolactone also been 26	
tested in the low risk group this could have increased the power but would also have exposed many 27	
without progression to the medication. As the low risk group was not randomised to spironolactone 28	
or placebo the trial cannot asses if spironolactone could be beneficial in this population or if 29	
screening and treatment is superior to non-screening, which would be particularly relevant if 30	
spironolactone had shown benefit. The major strengths of the study include a large, well-31	
phenotyped cohort, prospective study design with up to 4·5 years follow-up. In the protocol 32	
18	
	
additional unblinded follow up was anticipated, but independent of the findings in the study, it has 1	
so far not been possible to fund further clinical follow-up. However, we are aiming for register 2	
based follow-up, where possible. The study was funded by an EU FP7 grant with time limits 3	
inherent in the grant which defined the stopping date, and without opportunity for funding of an 4	
extension. There was consistency in findings of CKD273 being associated with progression of 5	
albuminuria and loss of renal function. 6	
In conclusion, the urinary proteomic classifier CKD273 is associated with a 2·5 times increased risk 7	
for progression to microalbuminuria and impaired renal function during a median of 2·5 years of 8	
follow-up, in subjects with T2D and normoalbuminuria, independent of clinical characteristics. 9	
Spironolactone did not prevent progression of albuminuria in high-risk subjects.10	
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Figure 1 Study outline 1	
 2	
Figure 2 Progression to renal endpoints according to CKD273 status in the observational 3	
cohort 4	
Panel A shows high-risk (n=216) and low-risk (n=1559) type 2 diabetic subjects based on the 5	
urinary proteomic pattern CKD273 and their progression to confirmed microalbuminuria during 6	
follow up. After adjustment for baseline age, sex, HbA1c, systolic blood pressure, retinopathy, 7	
UACR and eGFR the hazard ratio was 2·48; 95% CI, 1·80 to 3·42; P<0·0001. Panel B shows 8	
progression to CKD stage 3 (eGFR<60 ml per minute per 1·73 m2) in participants with eGFR>60 9	
ml per minute per 1·73 m2 at baseline: high-risk (n=184) and low-risk (n=1423) . 10	
Figure 3 Effect of spironolactone on progression to renal endpoints in intention to treat 11	
population. In high-risk type 2 diabetic subjects randomised to spironolactone (n=102) or placebo 12	
(n=107). Panel shows progression to confirmed microalbuminuria. 13	
14	
25	
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Figure 2:  Panel A Microalbuminuria observational cohort 1	
 2	
 3	
 4	
 5	
 6	
 7	
 8	
 9	
No.	of	Participants	 	 	 	 	 	
High-risk	 216	 189	 157	 63	 13	
Low-risk	 1559	 1482	 1200	 394	 47	
 10	
Panel B Decline in renal function observational cohort 11	
 12	
 13	
 14	
 15	
 16	
 17	
 18	
 19	
No.	of	Participants	 	 	 	 	 	
High-risk	 184	 189	 157	 63	 13	
Low-risk	 1423	 1482	 1200	 394	 47	
 20	
 21	
 22	
23	
Hazard	ratio	2·48	(95%	CI,	1·80	to	3·42)	
p	<	0·0001	
Hazard	ratio	3·93	(95	%	CI,	2·81	to	5·50)	
p	<	0·0001		
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Figure 3 Microalbuminuria events in the high-risk intention to treat cohort 2	
 3	
 4	
 5	
 6	
 7	
 8	
 9	
No. of Participants      
High-risk placebo 102 98 79 33 6 
High-risk spironolactone 107 86 74 29 7 
 10	
 11	
 12	
Hazard	ratio	0·808	(95%	CI,	0·49	to	1·34)		
p	=	0·409	
Table 1 Baseline characteristics by CKD273 subgroup and treatment 
 
 
Low-risk 
n = 1559 
High-riska,b, 
Spironolactone 
n = 102 
High-riska,b, 
Placebo 
n = 107 
Male sex 955 (61) 69 (68) 78 (73) 
Age, years 61 (9) 63 (6) 63 (7) 
Known diabetes duration, years 11 (8) 14 (8) 14 (9) 
Body mass index, kg/ m2 30 (5) 30 (5) 31 (6) 
Systolic blood pressure, mmHg 133 (12) 135 (12) 134 (12) 
Diastolic blood pressure, mmHg 78 (9) 79 (9) 79 (9) 
eGFR, ml per minute per 1·73 
m2 
88 (15) 81 (15) 82 (19) 
UACR, mg/ g 5 (3–8) 7 (4–12) 7 (4–12) 
Potassium, mmol/ L 4·2 (0·4) 4·3 (0·5) 4·2 (0·4) 
Sodium, mmol/ L 140 (3) 139 (3) 140 (3) 
HbA1c, mmol/ mol 57 (12) 58 (13) 59 (13) 
HbA1c, % 7·3 (1·1) 7·5 (1·2) 7·5 (1·2) 
Total cholesterol, mmol/ L 4·4 (1·0) 4·4 (1·1) 4·3 (1·1) 
HDL cholesterol, mmol/ L 1·2 (0·3) 1·2 (0·3) 1·2 (0·4) 
LDL cholesterol, mmol/ L 2·4 (0·9) 2·4 (1·1) 2·3 (1·0) 
Triglycerides, mmol/ L 1·6 (1·1-2·3) 1·8 (1·2-2·6) 1·7 (1·2–2·6) 
 
 
 
 
 
 
 
 
Mean (SD) or median (IQR) for continuous variables, n (%, rounded) for categorical variables. Low-risk: 
CKD273 continuous-classifier below or equal to the cut-point of 0·154. High-risk: CKD273-classifier above the 
cut-point of 0·154. aCompared to baseline description 15 two participants were excluded in the high-risk group 
after inspection was not able to identify informed consent forms. bHigh-risk CKD273 was identified in 216 
participants of whom 209 were randomized to intervention. See table S2 for baseline data in all 216. eGFR 
denotes estimated glomerular filtration rate, UACR Urine Albumin-to-Creatinine Ratio, ACEi angiotensin-
converting-enzyme inhibitors and ARB angiotensin-II-receptor blockers 
CKD273, arbitrary units -0·4 (0·3) 0·4 (0·2) 0·3 (0·2) 
Smoking status Current: 223 (14) 
Never: 861 (55) 
Former: 468 (30) 
Unknown: 7 (< 1) 
Current: 12 (12) 
Never: 56 (55) 
Former: 34 (33) 
Unknown: 0 
Current: 8 (7) 
Never: 56 (52) 
Former: 43 (40) 
Unknown: 0 
ACEi/ARB 952 (61) 90 (88) 93 (87) 
Follow-up time, years 2·5 (2·0-3·0) 2·5 (2·1-3·0) 2·5 (2·0-3·1) 
 
Table 2 Primary and secondary outcomes in the observational cohort and in the intention to treat cohort. 
Observational cohort 
Low-risk 
n = 1559 
High-risk 
n = 216 
Hazard ratio 
(95% CI) 
p value 
Primary endpoint: Microalbuminuria 
confirmed, n (%) 
139 (8·9) 61 (28·2) 3·92 (2·90 to 
5·30) 
<0·0001 
Secondary endpoints     
Microalbuminuria (single value), n (%) 288 (18·5) 99 (45·8) 3·68 (2·93 to 
4·62) 
<0·0001 
Macroalbuminuria (confirmed), n (%) 22 (1·4) 2 (0·01) 0·66 (0·15 to 
2·81) 
0·57  
CKD stage3 
(eGFR<60ml/min/1·73m2)*, n (%) 
119 (7·6) 48 (22·2) 3·50 (2·50 to 
4·90) 
<0·0001 
Fatal and non-fatal cardiovascular 
outcome†, n (%) 
53 (3·4) 12 (5·6) 1·77 (0·92 to 
3·22) 
0·089 
Ischaemic heart disease, n (%) 24 (1·5) 7 (3·2) 2·22 (0·96 to 
5.2) 
0·063 
Stroke, n (%) 15 (0·96) 4 (1·9) 1·99 (0·66 to 
6·0) 
0·22 
Congestive heart failure, n (%) 8 (0·51) 2 (0·93) 1·96 (0·42) to 
9·21) 
0·72 
All-cause mortality, n (%) 11 (0·62) 2 (0·93) 1·41 (0·31 to 
6·37) 
0·65 
Development of retinopathy or laser 144 (9·2) 21 (9·7) 1·02 (0·65 to 0·93 
treatment (self-reported), n (%) 1·62) 
Retinopathy, n (%) 101 (6·5) 14 (6·5) 0·96 (0·55 to 
1·68) 
0·89 
Laser treatment, n (%) 54 (3·5) 9 (4·2) 1·21 (0·56 to 
2·44) 
0.60 
   Difference 
(95% CI) 
 
Change in u-albumin /creatinine ratio  
(%/year)(SE) 
2·6 (0·85)  7·1 (1·14)  4·5 (2·7 to 
6·2) 
<0·0001 
Change in eGFR, ml/minute per 1·73 m2 
per year (SE) 
0·47 (0·19)  1·37 (0·34)   0·90 (0·14 to 
1·67)  
0·206 
   
  
High risk randomised (Intention to 
treat cohort) 
High-risk 
Spironolactone 
n = 102 
High-risk 
Placebo 
n = 107 
Hazard ratio 
(95% CI) 
p value 
Primary endpoint:  
Microalbuminuria confirmed n (%) 
26 (26) 35 (33) 0·81(0·49 to 
1·34) 
0·41 
Secondary endpoints     
Microalbuminuria (single value), n (%) 42 (41) 57 (53) 0·76 (0·51 to 
1·14) 
0·18 
Macroalbuminuria (confirmed), n (%) 0 2 (2) 0·00 (0·00 to 
5·59) 
0·52 
CKD stage 3 (eGFR<60ml/min/1·73 
m2)*, n (%) 
33 (32) 15 (14) 2·88 (1·56 to 
5·30)  
0·0007 
Fatal and non-fatal cardiovascular 
outcome†, n (%) 
4 (4) 8 (7) 0·57 (0·17 to 
1·88) 
0·35 
Ischaemic heart disease, n (%) 4 (4) 3 (3) 1·45 (0·33 to 
6·7) 
0·60 
Stroke, n (%) 0 (0) 4 (3·7) 0·00 (0·00 to 
1·59) 
0·14 
Congestive heart failure, n (%) 1 (1) 1 (1) 1·14 (0·071 
to 18·2)  
0·93 
All-cause mortality, n (%) 1 (1) 1 (1) 1·13 (0·071 
to 18·1) 
0·93 
Development of retinopathy or laser 
treatment (self-reported), n (%) 
14 (14) 4 (4) 2·82 (1·08 to 
7·4) 
0·034 
Retinopathy, n (%) 9 (9) 4 (4) 2·71 (0·84 to 
8.82) 
0.097 
Laser treatment, n (%) 9 (9) 2 (2) 4.22 (0.88 to 
20.3) 
0.073 
   Difference 
(95% CI) 
 
Change in urinary albumin/creatinine 
ratio %/year (SE) 
6·8 (2·5)  6·4 (2·3) 0·38 (-6·2 to 
7·0) 
0·91 
Change in eGFR,  
ml/minute per 1·73 m2 per year (SE) 
-1·52 (0·54) -1·33 (0·49) 0·18 (-1·25 to 
1·60) 
0·80 
Change in eGFR from week 13, 
ml/minute per 1·73 m2 per year (SEM) 
-1·33 (0·68)  -1·26 (0·64) 0·073 (-1·8 to 
2·0) 
0·94 
*For patients with eGFR >60 ml/min/1·73m2 at baseline· Data are numbers (%) or mean (SE). SE denotes 
standard error of the mean. 
†Comparison of composite fatal and non-fatal cardiovascular outcome (MI, stroke, CABG, PTCA, 
hospitalization for heart failure and CVD), and all-cause mortality during the study) 
	
Table 3 Adverse events in intention to treat cohort (high risk randomised to placebo or spironolactone). 
 
 
High-risk 
Spironolactone 
n = 102 
High-risk 
Placebo 
n = 107 
Any adverse events (total number) 312 321 
Any adverse events (patients with at least one) 82 (82) 86 (80) 
Adverse events leading to discontinuation of study drug 25 (25) 10 (9) 
Any serious adverse event  
(patients with at least one) 
34 (33) 22 (21) 
Any serious adverse event 17 (17) 21 (20) 
Serious adverse event considered related to study drug 2 (2) 1 (1) 
Death 1 (1) 1 (1) 
Events of special interest:   
Hyperkalaemia 9 (9) 1 (1) 
Event of s-potassium > 5·5 mmol/L 13 (13) 4 (4) 
Gynecomastia 3 (3) 0 (0) 
Hypotension 3 (3) 1 (1) 
Development of CKD 3 (eGFR <60 ml/min/1·73m2) 33 (32) 15 (14) 
Development of CKD 4 (eGFR<30 ml/min/1·73m2) 3 (3) 4 (4) 
30% decline in eGFR from baseline 24 (24) 18 (17) 
40% decline in eGFR from baseline 7 (7)  8 (7) 
Data	are	numbers	(%)	of	adverse	events	unless	stated	otherwise. 
